Main Article Content
Abstract
Introduction: Transarterial chemoembolization (TACE) is a widely used treatment for unresectable hepatocellular carcinoma (HCC). This study aimed to evaluate the long-term outcomes of TACE in a cohort of patients with HCC in Beijing, China.
Methods: This retrospective cohort study included patients who underwent TACE for HCC at a tertiary care hospital in Beijing, China, between 2010 and 2018. Data on patient demographics, tumor characteristics, treatment details, and outcomes were collected from medical records. Overall survival (OS) and progression-free survival (PFS) were the primary endpoints. Survival analysis was performed using the Kaplan-Meier method and Cox proportional hazards regression.
Results: A total of 352 patients were included in the study. The median follow-up duration was 48 months (range: 6-120 months). The median OS was 36 months, and the 5-year OS rate was 28%. The median PFS was 12 months, and the 3-year PFS rate was 15%. Tumor size, Barcelona Clinic Liver Cancer (BCLC) stage, and alpha-fetoprotein (AFP) level were independent predictors of OS and PFS.
Conclusion: TACE can provide long-term survival benefits for patients with HCC in Beijing, China. Tumor size, BCLC stage, and AFP level are important prognostic factors for TACE outcomes.
Keywords
Article Details
Sriwijaya Journal of Radiology and Imaging Research (SJRIR) allow the author(s) to hold the copyright without restrictions and allow the author(s) to retain publishing rights without restrictions, also the owner of the commercial rights to the article is the author.